Savant Capital LLC Has $2.91 Million Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Savant Capital LLC boosted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 81.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,755 shares of the company’s stock after purchasing an additional 3,943 shares during the quarter. Savant Capital LLC’s holdings in Medpace were worth $2,909,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in MEDP. Pallas Capital Advisors LLC increased its stake in shares of Medpace by 179.7% in the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock valued at $1,086,000 after acquiring an additional 2,101 shares during the last quarter. Baillie Gifford & Co. increased its stake in Medpace by 175.6% in the third quarter. Baillie Gifford & Co. now owns 14,876 shares of the company’s stock valued at $4,966,000 after purchasing an additional 9,478 shares in the last quarter. Barclays PLC raised its holdings in Medpace by 71.9% in the third quarter. Barclays PLC now owns 19,781 shares of the company’s stock worth $6,603,000 after purchasing an additional 8,275 shares during the period. Oppenheimer Asset Management Inc. boosted its position in shares of Medpace by 6.3% during the third quarter. Oppenheimer Asset Management Inc. now owns 45,473 shares of the company’s stock worth $15,179,000 after purchasing an additional 2,675 shares in the last quarter. Finally, CWA Asset Management Group LLC acquired a new position in shares of Medpace in the 3rd quarter valued at $1,306,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Performance

NASDAQ MEDP opened at $327.86 on Wednesday. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77. The stock’s 50 day moving average price is $344.13 and its two-hundred day moving average price is $349.34. The stock has a market capitalization of $10.19 billion, a price-to-earnings ratio of 28.71, a PEG ratio of 1.85 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 17.66% and a return on equity of 50.87%. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

Analyst Upgrades and Downgrades

MEDP has been the topic of several research analyst reports. Robert W. Baird raised their price objective on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. William Blair reaffirmed an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Baird R W lowered Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Finally, TD Cowen dropped their target price on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, Medpace presently has an average rating of “Hold” and an average target price of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.